News

  • 13 March 2013

    Sequana Medical is pleased to announce that Prof. Giorgio Enrico Gerunda from the University of Modena and Reggio Emilia has implanted Italy’s first two patients with the alfapump system. The alfapump system is a fully implantable battery-powered pump that is designed to remove excess abdominal fluid, known as ascites, that collects in patients suffering from advanced liver disease. 

  • 5 March 2013

    Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, announced today that it has secured an additional USD 4.3 million/CHF 4 million in series C financing from a new strategic industry partner. This second successful closing brings the total in series C funds raised to USD 44.6 million/CHF 41.4 million.

  • 28 February 2013

    Santhera Pharmaceuticals (SIX: SANN) announced today that following the voluntary withdrawal of Catena® from the Canadian market and the earlier negative decision of the Committee for Medicinal Products for Human Use (CHMP) on the Market Authorization Application for Raxone® in Leber's Hereditary Optic Neuropathy (LHON), the Board has decided to consider strategic options including product licensing for Raxone® in LHON and the possibility of a merger or acquisition. Santhera has already received expressions of interest from third parties and has retained Piper Jaffray Limitedto assist the Company in this process.

  • 27 February 2013

    Santhera Pharmaceuticals (SIX: SANN) announced today the voluntary withdrawal of Catena® from the Canadian market. This decision follows review of additional data from clinical trials in patients with Friedreich's Ataxia, and subsequent consultation with Health Canada.

  • 1 February 2013

    Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its new generation TactiCath Quartz contact-force sensing ablation catheter has been used for the first time in the United States by Dr. J. Michael Mangrum at University of Virginia Medical Center in Charlottesville, Va. The first U.S. case was performed on January 31 as part of an amended protocol of the company’s TOCCASTAR investigational device exemption (IDE) clinical study of the TactiCath (called the "TOCCASTAR Supplemental Clinical Study"). The supplemental study’s protocol is identical to that of original TOCCASTAR study, with the exception that the patients treated with the newer device will not be randomized.